Content of hypericin and hyperforin determined by HPLC-UV
Percentage of hypericin or hyperforin content given in the compendium was converted to content per 100 mg extract. For quantification by HPLC, a standard curve was used to calculate the concentration of hypericin or hyperforin, respectively. Data from quantification are from three independent experiments.
| Formulation (Tradename) | Hypericina (Declared Content) | Hypericina (Quantified by HPLC) | Hyperforinb (Declared Content) | Hyperforinb (Quantified by HPLC) | ||
|---|---|---|---|---|---|---|
| mg/100 mg | mg/100 mg | ± S.D. | mg/100 mg | mg/100 mg | ± S.D. | |
| ARKOCAPSc | 0.3 | 0.09 | ± 0.04 | — | 0.24 | ± 0.01 |
| DEPRIVITAd | 0.1–0.3 | 0.18 | ± 0.01 | — | 1.04 | ± 0.05 |
| HAENSELER MENOPAUSEe | 0.1–0.3 | 0.10 | ± 0.01 | — | 0.34 | ± 0.01 |
| HYPERIPLANTf | 0.1–0.3 | 0.15 | ± 0.02 | 36 | 1.62 | ± 0.03 |
| JARSINg | 0.1–0.3 | 0.20 | ± 0.02 | — | 0.70 | ± 0.02 |
| REBALANCEh | 0.1–0.3 | 0.08 | ± 0.01 | <0.2 | 0.02 | ± 0.01 |
| REMOTIVh | 0.1–0.3 | 0.09 | ± 0.01 | <0.2 | 0.02 | ± 0.01 |
| SANDOZ HYPERICUMi | 0.1–0.3 | 0.21 | ± 0.02 | — | 0.85 | ± 0.04 |
| SOLEVITAd | 0.1–0.3 | 0.16 | ± 0.03 | — | 1.02 | ± 0.07 |
| VOGEL HYPERIMEDj | 0.5–0.8 | 0.08 | ± 0.01 | — | — | — |
| VOGEL HYPERIFORCEj | 0.2–2.1 | 0.08 | ± 0.01 | — | — | — |
↵a The content of hypericin corresponds to the sum of the content of hypericin and pseudohypericin.
↵b The content of hyperforin corresponds to the sum of the content of hyperforin and adhyperforin.
↵c Arko Diffusion SA, Les Avacias, Switzerland.
↵d Permamed AG, Therwil, Switzerland.
↵e Hänseler AG, Herisau, Switzerland.
↵f Schwabe Pharma AG, Küssnacht, Switzerland.
↵g Vifor SA, Bern, Switzerland.
↵h Zeller AG, Romanshorn, Switzerland.
↵i Sandoz Pharmaceuticals AG, Holzkirchen, Germany.
↵j Bioforce AG, Roggwil, Switzerland.